Hims & Hers Health, Inc. (NYSE:HIMS) Receives $37.31 Average Target Price from Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has earned a consensus recommendation of “Hold” from the fifteen analysts that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $37.31.

HIMS has been the topic of several analyst reports. BTIG Research began coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target on the stock. Bank of America lifted their target price on Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research report on Tuesday, March 18th. Needham & Company LLC raised their price objective on Hims & Hers Health from $31.00 to $61.00 and gave the stock a “buy” rating in a research note on Tuesday, February 25th. Leerink Partners lifted their price objective on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research report on Tuesday, February 25th. Finally, Piper Sandler increased their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, February 25th.

Hims & Hers Health Trading Down 8.8 %

Shares of HIMS opened at $29.11 on Wednesday. The firm has a fifty day simple moving average of $39.88 and a two-hundred day simple moving average of $29.37. The firm has a market cap of $6.47 billion, a PE ratio of 66.15 and a beta of 1.37. Hims & Hers Health has a 1-year low of $11.20 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. As a group, research analysts forecast that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Soleil Boughton sold 268,932 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the sale, the insider now directly owns 169,803 shares of the company’s stock, valued at $4,712,033.25. This represents a 61.30 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 11,581 shares of the firm’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $24.44, for a total transaction of $283,039.64. Following the completion of the transaction, the chief financial officer now directly owns 118,077 shares of the company’s stock, valued at approximately $2,885,801.88. This trade represents a 8.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,061,718 shares of company stock valued at $37,894,395 in the last 90 days. Insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

A number of large investors have recently made changes to their positions in HIMS. Vanguard Group Inc. grew its position in Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock worth $489,817,000 after acquiring an additional 2,020,722 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 64,338.5% in the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company’s stock worth $202,556,000 after purchasing an additional 8,364,000 shares during the period. Renaissance Technologies LLC increased its position in shares of Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company’s stock valued at $168,079,000 after purchasing an additional 1,562,302 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Hims & Hers Health by 192.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock valued at $152,436,000 after buying an additional 4,145,305 shares during the period. Finally, State Street Corp raised its holdings in Hims & Hers Health by 4.7% during the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after buying an additional 206,078 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.